{"id":389956,"date":"2021-12-06T00:00:00","date_gmt":"2021-12-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2021-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2021\/"},"modified":"2026-05-16T11:28:43","modified_gmt":"2026-05-16T11:28:43","slug":"dlsfon0005-2021-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2021-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2021\/","title":{"rendered":"Multiple Myeloma | Disease Landscape and Forecast | G7 | 2021"},"content":{"rendered":"<p>The multiple myeloma therapy market continues to grow, fueled by the disease\u2019s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease\u2019s treatment algorithm. Although Revlimid and bortezomib remain the cornerstones of treatment, recently approved therapies (GlaxoSmithKline\u2019s Blenrep, Sanofi\u2019s Sarclisa, and Bristol Myers Squibb \/ Bluebird Bio\u2019s Abecma) have expanded the number of options available. The anti-BCMA bispecific agents (e.g., Pfizer\u2019s elranatamab and Janssen\u2019s teclistamab) in addition to the CAR T-cell therapies (e.g., Janssen\u2019s ciltacabtagene autoleucel) are also expected to compete fiercely, along with AbbVie \/ Roche\u2019s Venclexta \/ Venclyxto. Nevertheless, clinical and commercial potential exists for multiple myeloma therapies with improved efficacy, a novel mechanism of action, and\/or the ability to treat underserved patient segments, such as smoldering multiple myeloma.<\/p>\n<p><strong>Questions Answered <\/strong><\/p>\n<ul>\n<li>What is the size of the drug-treatable multiple myeloma population, and how do the drug-treatment rates vary by geography, line of therapy, and over time?<\/li>\n<li>How will the use of Revlimid and bortezomib change over the forecast period?<\/li>\n<li>What impact will the generic entry of these pivotal agents have on the multiple myeloma market?<\/li>\n<li>What are thought leaders\u2019 opinions of anti-BCMA agents that are approved or are in Phase II \/ III development, such as the BCMA-targeting antibody-drug conjugate, Blenrep; the CAR T-cell therapies, Abecma and ciltacabtagene autoleucel; and\u00a0bispecific agents,\u00a0elranatamab and teclistamab?<\/li>\n<li>What are the drivers of, and constraints on, the multiple myeloma market? How will the entry of new antimyeloma agents shape the market?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p><strong>Scope<\/strong><\/p>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research:<\/strong>\u00a032\u00a0country-specific interviews with experts and country-specific surveys with 210 hematologist-oncologists treating multiple myeloma.<\/p>\n<p><strong>Epidemiology:<\/strong> Incidence of multiple myeloma by country, segmented by symptom.<\/p>\n<p><strong>Emerging therapies:<\/strong><strong> <\/strong> Phase III\/PR: 4 drugs; coverage of select Phase I and II products.<\/p>\n","protected":false},"template":"","class_list":["post-389956","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389956\/revisions"}],"predecessor-version":[{"id":576347,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389956\/revisions\/576347"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}